Home » Stocks » ALIM

Alimera Sciences, Inc. (ALIM)

Stock Price: $4.35 USD 0.15 (3.57%)
Updated Oct 30, 2020 12:38 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 21.89M
Revenue (ttm) 54.77M
Net Income (ttm) -6.39M
Shares Out 5.03M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $4.35
Previous Close $4.20
Change ($) 0.15
Change (%) 3.57%
Day's Open 4.11
Day's Range 4.11 - 4.45
Day's Volume 2,329
52-Week Range 0.00 - 9.98

More Stats

Market Cap 21.89M
Enterprise Value 52.30M
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 5.03M
Float 4.43M
EPS (basic) -1.29
EPS (diluted) -1.30
FCF / Share -0.72
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 31,489
Short Ratio 2.21
Short % of Float 0.71%
Beta 2.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.40
PB Ratio n/a
Revenue 54.77M
Operating Income -1.37M
Net Income -6.39M
Free Cash Flow -3.61M
Net Cash -30.41M
Net Cash / Share -6.04
Gross Margin 86.39%
Operating Margin -2.50%
Profit Margin -11.70%
FCF Margin -6.59%
ROA -1.94%
ROE n/a
ROIC -2.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(210.34% upside)
Current: $4.35
Target: 13.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth15.76%29.76%4.6%53.01%166.39%349.95%----
Gross Profit47.3242.2932.4731.9920.686.980.01---
Operating Income-5.27-9.67-16.45-27.85-39.00-32.95-34.40-22.04-21.41-22.07
Net Income-10.44-16.38-22.00-33.17-30.65-35.91-46.23-19.75-22.52-13.86
Shares Outstanding4.775.874.473.522.962.692.
Earnings Per Share-2.193.71-4.95-9.45-10.35-13.65-24.30-9.45-10.80-11.55
Operating Cash Flow-4.15-11.55-12.87-25.10-45.36-24.30-37.82-21.18-20.72-22.05
Capital Expenditures-0.17-0.18-0.24-0.19-0.45-0.84-0.97-0.02-0.11-0.13
Free Cash Flow-4.33-11.73-13.11-25.29-45.82-25.14-38.79-21.21-20.83-22.18
Cash & Equivalents9.4613.0824.1031.0131.1176.7012.6349.5633.6154.84
Total Debt39.0138.4134.7533.5532.6033.354.872.985.345.94
Net Cash / Debt-29.55-25.34-10.65-2.54-1.4943.347.7646.5828.2748.91
Book Value-4.452.7214.9225.5926.3249.52-4.9339.1424.9845.21
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alimera Sciences, Inc.
Country United States
Employees 122
CEO Richard S. Eiswirth

Stock Information

Ticker Symbol ALIM
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ALIM
IPO Date April 22, 2010


Alimera Sciences, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.